Andera Partners Co-Leads $196 Million Round for Kestra Medical

Andera Partners has co-led a $196 million financing round for Kestra Medical. This funding aims to accelerate the commercialization of Kestra’s wearable defibrillator. The round saw participation from Ally Bridge Group, Longitude Capital, Omega Funds, and new investors, including T. Rowe Price Investment Management, Inc., Eventide Asset Management, and Gilmartin Capital. Long-time investors Bain Capital and Endeavour Vision also contributed significantly.

Additionally, Raymond W. Cohen, CEO of Axonics, has joined Kestra Medical's board as an independent member. Cohen brings over 40 years of experience in the life sciences industry. His previous roles include CEO positions at Vessix Vascular and Cardiac Science Inc., both successfully acquired by Boston Scientific.

Cohen expressed enthusiasm for Kestra’s product and its market potential, indicating a readiness to compete with Zoll Medical. He looks forward to leveraging his expertise to support Kestra’s ambitions in the wearable cardioverter defibrillator sector.